[1]LOUIS DN,PERRY A,WESSELING P,et al.The 2021 WHO classification of tumors of the central nervous system:a summary[J].Neuro Oncol,2021,23(8):1231-1251.
[2] HORBINSKI C,NABORS LB,PORTNOW J,et al.NCCN Guidelines Insights:Central nervous system cancers,version 2.2022[J].J Natl Compr Canc Netw,2023,21(1):12-20.
[3] OSTROM QT,PRICE M,NEFF C,et al.CBTRUS statistical report:Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019[J].Neuro Oncol,2022,24(Suppl 5):v1-v95.
[4] LAPOINTE S,PERRY A,BUTOWSKI NA.Primary brain tumours in adults[J].Lancet,2018,392(10145):432-446.
[5] TAN AC,ASHLEY DM,LOPEZ GY,et al.Management of glioblastoma:State of the art and future directions[J].CA Cancer J Clin,2020,70(4):299-312.
[6] KAYNAK A,DAVIS HW,VALLABHAPURAPU SD,et al.SapC-DOPS as a novel therapeutic and diagnostic agent for glioblastoma therapy and detection:Alternative to old drugs and agents[J].Pharmaceuticals(Basel),2021,14(11):1193.
[7] FURNARI FB,CLOUGHESY TF,CAVENEE WK,et al.Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma[J].Nat Rev Cancer,2015,15(5):302-310.
[8] CHANDRAN M,CANDOLFI M,SHAH D,et al.Single vs.combination immunotherapeutic strategies for glioma[J].Expert Opin Biol Ther,2017,17(5):543-554.
[9] BHUJBAL SV,DE VOS P,NICLOU SP.Drug and cell encapsulation:alternative delivery options for the treatment of malignant brain tumors[J].Adv Drug Deliv Rev,2014,67-68:142-153.
[10] CHEREVAN AS,NANDAN SP,ROGER I,et al.Polyoxometalates on functional substrates:Concepts,synergies,and future perspectives[J].Adv Sci(Weinh),2020,7(8):1903511.
[11] COLOVIC MB,LACKOVICM,LALATOVIC J,et al.Polyoxometalates in biomedicine:Update and overview[J].Curr Med Chem,2020,27(3):362-379.
[12] LI XH,CHEN WL,LI YG,et al.Multifunctional rare earth-containing polyoxometalates achieving high-efficiency tumor therapy and visual fluorescence monitoring[J].Inorganic Chemistry Communications,2019,104(6):40-47.
[13] BIJELIC A,AURELIANO M,ROMPEL A.Polyoxometalates as potential next-generation metallodrugs in the combat against cancer[J].Angew Chem Int Ed Engl,2019,58(10):2980-2999.
[14] JIA D,GONG L,LI Y,et al.{BiW8O30} exerts antitumor effect by triggering pyroptosis and upregulating reactive oxygen species[J].Angew Chem Int Ed Engl,2021,60(39):21449-21456.
[15]祝欣萍,贾迪,林少辉,等.新型多金属氧酸盐药物{BiW8O30}对肝癌SK-HEP-1细胞的抑制作用[J].癌变·畸变·突变,2022,34(01):47-52,66.
ZHU XP,JIA D,LIN SH,et al.Inhibitory effects of a novelpolyoxometalate drug {BiW8O30}on liver cancer SK-HEP-1 cells[J].Carcinogenesis,Teratogenesis & Mutagenesis,2022,34(01):47-52,66.
[16] OBEXER P,AUSSERLECHNER MJ.X-linked inhibitor of apoptosis protein-a critical death resistance regulator and therapeutic target for personalized cancer therapy[J].Front Oncol,2014,4:197.
[17] AFROZE N,PRAMODH S,SHAFARIN J,et al.Fisetin deters cell proliferation,induces apoptosis,alleviates oxidative stress and inflammation in human cancer cells,HeLa[J].Int J Mol Sci,2022,23(3):1707.
[18] LU KW,LU TJ,CHUEH FS,et al.Allyl isothiocyanate(AITC) induces apoptotic cell death in vitro and exhibits anti-tumor activity in a human glioblastoma GBM8401/luc2 model[J].Int J Mol Sci,2022,23(18):10411.
[19] ZHANG ZM,DUAN X,YAO S,et al.Cation-mediated optical resolution and anticancer activity of chiral polyoxometalates built from entirely achiral building blocks[J].Chem Sci,2016,7(7):4220-4229.
[20] YAN HF,ZOU T,TUO QZ,et al.Ferroptosis:mechanisms and links with diseases[J].Signal Transduct Target Ther,2021,6(1):49.
[21] 庞敬瑶,李佩玲,Beilerli Aferin,等.基于铁死亡的癌症治疗新策略[J].现代肿瘤医学,2021,29(06):1058-1061.
PANG JY,LI PL,BEILERLI AFERIN,et al.New strategies of cancer therapy based on ferroptosi[J].Modern Oncology,2021,29(06):1058-1061.